Vertex reports second positive pivotal Phase III study for HCV protease inhibitor telaprevir
This article was originally published in Scrip
Executive Summary
Vertex has released positive results from the second Phase III study of the investigational hepatitis C protease inhibitor telaprevir, showing that for those patients who responded to the drug early on in treatment, a total of 24 weeks' therapy was just as effective as 48 weeks.